Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares.
The article highlights our Company’s strong position for the future with generous coverage of recently published PAT-DX1 data from our collaboration with Yale School of Medicine in the ‘Journal of Clinical Investigation – Insight’.
Of particular interest is the author’s mention of our potential R&D program expansion and commercial reach: ‘Developing additional programs is not just risk mitigation for the main program, but also strengthens the company’s position for licensing deals and may allow discrete assets based on the core technology to be out-licensed.’